» Articles » PMID: 22953169

Towards Elimination of Asbestos-related Diseases: a Theoretical Basis for International Cooperation

Overview
Journal Saf Health Work
Date 2012 Sep 7
PMID 22953169
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

We develop a theoretical framework for international cooperation that can be used for the elimination of asbestos-related diseases (ARDs). The framework is based on the similarities in the temporal patterns of asbestos use and occurrence of ARDs in diverse countries. The status of each nation can be characterized by observing asbestos use and ARD frequency therein using a time window. Countries that supply technology for prevention of ARDs can be classified as donors and countries that receive these technologies as recipients. We suggest identification of three levels of core preventative technologies. Development of a common platform to gather and manage core preventative technologies will combine the strengths of donor countries and the needs of recipient countries.

Citing Articles

The Italian Experience in the Development of Mesothelioma Registries: A Pathway for Other Countries to Address the Negative Legacy of Asbestos.

Magnani C, Mensi C, Binazzi A, Marsili D, Grosso F, Ramos-Bonilla J Int J Environ Res Public Health. 2023; 20(2).

PMID: 36673690 PMC: 9858856. DOI: 10.3390/ijerph20020936.


Must countries shoulder the burden of mesothelioma to ban asbestos? A global assessment.

Chimed-Ochir O, Rath E, Kubo T, Yumiya Y, Lin R, Furuya S BMJ Glob Health. 2022; 7(12).

PMID: 36543384 PMC: 9772623. DOI: 10.1136/bmjgh-2022-010553.


Radiographic Changes in Colombian Asbestos Factory Workers.

Frank A, Villamizar G, Bustillo Pereira J Ann Glob Health. 2020; 86(1):3.

PMID: 31934550 PMC: 6952967. DOI: 10.5334/aogh.2634.


Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?.

Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N Eur Respir Rev. 2018; 27(147).

PMID: 29540495 PMC: 9488560. DOI: 10.1183/16000617.0098-2017.


Elimination of asbestos use and asbestos-related diseases: an unfinished story.

Park E, Takahashi K, Jiang Y, Movahed M, Kameda T Cancer Sci. 2012; 103(10):1751-5.

PMID: 22726320 PMC: 7659290. DOI: 10.1111/j.1349-7006.2012.02366.x.


References
1.
Nishikawa K, Takahashi K, Karjalainen A, Wen C, Furuya S, Hoshuyama T . Recent mortality from pleural mesothelioma, historical patterns of asbestos use, and adoption of bans: a global assessment. Environ Health Perspect. 2008; 116(12):1675-80. PMC: 2599762. DOI: 10.1289/ehp.11272. View

2.
Takahashi K . Asbestos-related diseases: time for technology sharing. Occup Med (Lond). 2008; 58(6):384-5. PMC: 2525509. DOI: 10.1093/occmed/kqn086. View

3.
Hodgson J, McElvenny D, Darnton A, Price M, Peto J . The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005; 92(3):587-93. PMC: 2362088. DOI: 10.1038/sj.bjc.6602307. View

4.
Peto J, Hodgson J, Matthews F, Jones J . Continuing increase in mesothelioma mortality in Britain. Lancet. 1995; 345(8949):535-9. DOI: 10.1016/s0140-6736(95)90462-x. View

5.
Murayama T, Takahashi K, Natori Y, Kurumatani N . Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med. 2005; 49(1):1-7. DOI: 10.1002/ajim.20246. View